Edition:
United States

Divya Grover

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

12:24pm EDT

Celgene MS drug clears key trial, but disability data falls short

Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

May 17 2017

FDA places clinical hold on Concert Pharma's hair loss drug

Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration (FDA) imposed a clinical hold on a trial testing the company's drug to treat alopecia areata, a type of hair loss.

May 10 2017

INC Research to merge with inVentiv in latest contract medical research deal

INC Research Holdings Inc said on Wednesday it would merge with private equity-owned inVentiv Health Inc, a fellow contract research services provider, in a $4.6 billion all-stock deal to help it win contracts with large pharma companies.

May 09 2017

New generic drugs power Endo's results; shares jump

Endo International Plc reported a higher-than-expected quarterly adjusted profit, driven by strong demand for its newly launched generic drugs, sending its shares up more than 16 percent.

May 09 2017

New generic drugs power Endo's results; shares jump

Endo International Plc reported a higher-than-expected quarterly adjusted profit, driven by strong demand for its newly launched generic drugs, sending its shares up more than 16 percent.

May 09 2017

New generic drugs power Endo's results; shares jump

Endo International Plc reported a higher-than-expected quarterly adjusted profit, driven by strong demand for its newly launched generic drugs, sending its shares up more than 16 percent.

May 05 2017

New Mountain Capital to take lab supplies company VWR private

Avantor, owned by private equity firm New Mountain Capital, will buy VWR Corp for about $4.38 billion, creating a laboratory equipment giant supplying everything from test tubes to microscopes to the healthcare and technology industries.

May 04 2017

As Eylea fears fade, focus turns to Regeneron's eczema drug

Regeneron Pharmaceuticals Inc said its eczema drug Dupixent was off to a strong start and the biotech stood by its full-year sales forecast for its flagship drug Eylea even as competition heats up.

May 03 2017

WellCare shares pop after bigger-than-expected profit

WellCare Health Plans Inc reported a quarterly profit that blew past analysts' estimates, helped by higher enrolments in all its plans and lower costs in its Medicare business, sending its shares up as much as 4.7 percent.

May 02 2017

Prescription for growth at Pfizer? Analysts say, deals

Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.

More From Around the Web

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary